Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T collaboration with MSK to develop mesothelin-targeted CAR T using novel co-stimulatory …